| Tissue-type plasminogen activator therapy versus primary coronary angioplasty: impact on myocardial tissue perfusion and regional function 1 month after uncomplicated myocardial infarction. | |
| | |
MedLine Citation:
|
PMID: 9462577 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: This study sought to compare the impact of primary coronary angioplasty and thrombolytic therapy for acute myocardial infarction (AMI) on 1-month infarct size and microvascular perfusion. BACKGROUND: The effect of the reperfusion strategies of primary coronary angioplasty and thrombolytic therapy on microvascular integrity still remains to be determined. METHODS: Sixty-two consecutive patients with a first AMI, undergoing intravenous tissue-type plasminogen activator (t-PA) therapy (32 patients, Group I) or primary angioplasty (30 patients, Group II), were studied. Only patients with 1-month Thrombolysis in Myocardial Infarction (TIMI) flow grade 2 or 3 were selected for the study. Patients in whom primary angioplasty was unsuccessful or those with clinical evidence of failed reperfusion were excluded. Microvascular perfusion was assessed at 1 month by intracoronary injection of sonicated microbubbles. Contrast score index (CSI) and wall motion score index (WMSI) were derived using qualitative methods. RESULTS: At baseline there were no significant differences between groups for age, risk factors, time to hospital presentation, Killip class on admission, prevalence of multivessel disease or anterior infarct site, infarct area extension before reperfusion, peak creatine kinase levels and postinfarction treatment. Conversely, significant differences between groups were found at follow-up for percent residual infarct related-artery (IRA) stenosis (70 +/- 12 vs 36 +/- 14 [mean +/- SD], p = 0.0001), CSI (1.02 +/- 0.4 vs. 1.49 +/- 0.5, p = 0.0003) and WMSI (1.67 +/- 0.3 vs. 1.45 +/- 0.3, p = 0.015). In particular, in the subset of patients with TIMI grade 3 flow, a perfusion defect occurred in one or more segments subtended by the IRA in 72% of Group I versus 31% of Group II patients (p < 0.00001) and in 27% of Group I versus 8% of Group II segments (p < 0.00001). CONCLUSIONS: The present study shows, in a highly selected cohort with successful IRA recanalization, that primary angioplasty is more effective than thrombolysis in preserving microvascular flow and preventing extension of myocardial damage at 1-month after AMI. |
| | |
Authors:
|
L Agati; P Voci; P Hickle; D C Vizza; C Autore; F Fedele; S B Feinstein; A Dagianti |
Related Documents
:
|
12072697 - Nitric oxide inhalation is useful in the management of right ventricular failure caused... 10994937 - Coronary angioplasty in patients with unstable angina: clinical, electrocardiographic a... 11567677 - Percutaneous coronary revascularisation in women. 2945677 - Early results of emergency surgery after coronary angioplasty. 19926047 - Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneo... 11333057 - Syncope in pharmacologically unmasked brugada syndrome: indication for an implantable d... |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: Journal of the American College of Cardiology Volume: 31 ISSN: 0735-1097 ISO Abbreviation: J. Am. Coll. Cardiol. Publication Date: 1998 Feb |
Date Detail:
|
Created Date: 1998-02-26 Completed Date: 1998-02-26 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8301365 Medline TA: J Am Coll Cardiol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 338-43 Citation Subset: AIM; IM |
Affiliation:
|
Department of Cardiology and Cardiac Surgery, La Sapienza University of Rome, Italy. agati@axrma.uniroma1.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Age Factors Angioplasty, Transluminal, Percutaneous Coronary* Cineradiography Cohort Studies Contrast Media / administration & dosage Coronary Angiography Coronary Circulation* Coronary Disease / pathology, physiopathology Coronary Vessels / pathology Creatine Kinase / analysis Echocardiography Female Follow-Up Studies Heart / physiopathology* Hospitalization Humans Injections, Intra-Arterial Injections, Intravenous Male Microcirculation Middle Aged Myocardial Infarction / drug therapy, pathology, physiopathology, therapy* Myocardium / pathology Patient Admission Plasminogen Activators / administration & dosage, therapeutic use* Risk Factors Thrombolytic Therapy* Tissue Plasminogen Activator / administration & dosage, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Contrast Media; EC 2.7.3.2/Creatine Kinase; EC 3.4.21.-/Plasminogen Activators; EC 3.4.21.68/Tissue Plasminogen Activator |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Comparison of technetium-99m tetrofosmin and thallium-201 single-photon emission computed tomographi...
Next Document: Assessing baroreflex sensitivity in post-myocardial infarction patients: comparison of spectral and ...